For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome
If you continue without changing your cookie settings, we'll assume you’re happy with this.
Whether you are a small biotech company, which has never brought a drug to market, or a multinational pharma, you can benefit from Abcam custom antibody discovery solutions as we remove much of the burden and eliminate the risk for you. As a platform-independent partner, we can support you as early as the discovery phase without requiring you to make a platform decision, thus decreasing your risk and increasing future options. Join Abcam experts Ole Olsen and Courtney Nicholson as they talk you through our custom antibody discovery platforms and how they can support the discovery needs of biopharma and diagnostics.
Interested in learning more? Get in touch!
Courtney Nicholson, Senior Director of Business Development | Abcam
Courtney focuses on the development of commercial partnerships with the industry through strategic programs and licensing collaborations that utilize Abcam’s expertise and novel development platforms. Working across the product portfolio, the team engages with partners working in disease research, diagnosis, and patient treatment development programs across a wide range of disease areas.
Working previously at Thermo-Fisher Scientific, Qiagen, and diagnostic start-up AgPlus Diagnostics, spun out of the National Physical Laboratory, Courtney has over 15 years of commercial experience working with the biotech, diagnostic and pharmaceutical industries. Her primary focus has been in technology development, licensing, and strategic partnerships, with experience across a variety of areas including infectious diseases, cardiac, brain injury, cancer, and prenatal testing.
Ole Olsen, Head of Custom Solutions | Abcam
Dr Olsen is the head of antibody profiling in the Custom Solutions Department at Abcam in Cambridge U.K. He leads the design and execution of all antibody discovery programs in Cambridge to find antibodies with exquisite properties to be utilized in many specialized assays.
Dr. Olsen completed his PhD at the University of British Columbia in Vancouver B.C. Canada and then entered the biotech industry to discover and develop therapeutic antibodies. Before joining Abcam in 2020, he has held various positions in his career, such as the head of the B cell culture Department at Immgenics Pharmaceuticals (1999-2000), head of the B cell culture and hybridoma department at Abgenix/Amgen (2000-2006), Senior Director of Antibody Operations at Theraclone Sciences (2006-2014), Consultant to the CSO at IgM Biosciences (2014-2015), Senior Director of Antibody Discovery at Systimmune Inc. (2015-2019), Vice-president of Antibody Discovery at iQ Biosciences (2019).